Merck (NYSE: MRK) + 1.5% After an hour WSJ Report that it has begun testing one of its experimental COVID-19 vaccine candidates in healthy volunteers.
The study, based in Belgium and seeking to enroll 260 subjects, was reported by Merck on a government database; It is expected to be completed in April 2022, although it may be finished very quickly.
Merck’s experimental shot contains a weaker version of the virus that causes measles, which he hopes will deliver coronovirus spike proteins to the immune system to help trigger the immune system.
The company has stated that it wants to develop a vaccine that provides protection with a single dose so that a second shot is not needed and uses a proven technology that can be easily extended to manufacture.
Pfizer Vaccines (NYSE: PFE) And partners BioNTech (NASDAQ: BNTX), more modern (NASDAQ: mRNA) Both use unproven mRNA gene-based technology and require two shots; Those vaccines, as well as a commentary from AstraZeneca (NYSE: AZN), Are in late stage clinical trials.